Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
VAXINANO currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 2 distinct examiners and 2 distinct art units. This distribution shows that each pending action is being handled by a different individual in a different section of the office, requiring the company to manage separate prosecution tracks simultaneously.
The busiest examiner for the portfolio is OGUNBIYI, OLUWATOSIN A, who is responsible for 1 busiest examiner pending office action. The presence of 2 distinct art units suggests the portfolio covers multiple specialized sub-sectors within biotechnology, as the 2 pending office actions are not concentrated under a single supervisory authority. Because the company is dealing with 2 distinct examiners, the prosecution strategy must be adapted to different individual preferences. This diversity in examiners and art units may lead to different examination timelines and outcomes for the company's active applications.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| PEEBLES, KATHERINE | 1 | 35.5% | +48.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251658 | THERAPEUTIC VACCINE COMPRISING A SPECIFIC ANTIGEN OF A DISEASE THAT DOES NOT AFFECT THE CENTRAL NERVOUS SYSTEM AND NANOPARTICLES, AND USE OF THE VACCINE | OGUNBIYI, OLUWATOSIN A | 20d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004980 | METHOD FOR PREPARING A VACCINE COMPOSITION FROM LYOPHILIZED ANTIGENS | PEEBLES, KATHERINE | 14d |
| 18251658 | THERAPEUTIC VACCINE COMPRISING A SPECIFIC ANTIGEN OF A DISEASE THAT DOES NOT AFFECT THE CENTRAL NERVOUS SYSTEM AND NANOPARTICLES, AND USE OF THE VACCINE | OGUNBIYI, OLUWATOSIN A | 20d |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18251658 | THERAPEUTIC VACCINE COMPRISING A SPECIFIC ANTIGEN OF A DISEASE THAT DOES NOT AFFECT THE CENTRAL NERVOUS SYSTEM AND NANOPARTICLES, AND USE OF THE VACCINE | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103Other | Final Rejection | 20d | Pending | May 03, 2023 |
| 18004980 | METHOD FOR PREPARING A VACCINE COMPOSITION FROM LYOPHILIZED ANTIGENS | PEEBLES, KATHERINE | 1617 | §103DP | Non-Final OA | 14d | Pending | Jan 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial